Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 371

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 7
Chunk 371
---
-based compensation

    110,290

    100,025

    10,265

    10
    %

    Facility- and technology-related expenses

    50,903

    44,090

    6,813

    15
    %

    Other

    43,093

    23,031

    20,062

    87
    %

    Roche collaboration reimbursement

    (1,427
    )

    (871
    )

    (556
    )

    64
    %

    Total selling, general and administrative expenses
     
    $
    557,872

    $
    481,871

    $
    76,001

    16
    %

-77-

Selling, general and administrative expenses for 2024 increased by $76.0 million, or 16%, compared with 2023. The increase was primarily driven by the following:

•$25.2 million increase in professional service expenses primarily related to ongoing litigation matters, our continuing expansion efforts and continuing efforts to commercialize ELEVIDYS;

•$14.2 million increase in compensation and other personnel expenses primarily due to changes in headcount; 

•$10.3 million increase in stock-based compensation expense primarily related to the achievement of performance conditions related to certain PSUs during the year ended December 31, 2024 and changes in headcount; 

•$6.8 million increase in facility- and technology-related expenses primarily due to our continuing expansion efforts; and

•$20.1 million increase in other expenses primarily due to the timing of charitable contribution activity.

Amortization of in-licensed rights

Amortization of in-licensed rights relates to the agreements we entered into with UWA, Nationwide, BioMarin and Parent Project Muscular Dystrophy in April 2013, December 2016, July 2017 and May 2018, respectively. Each in-licensed right is being amortized on a straight-line basis over the remaining life of the relevant patent from the date the related fee was incurred, either the regulatory approval or the first commercial sale of the applicable product. For 2024 and 2023, we recorded amortization of in-licensed rights of $2.4 million and $1.6 million, respectively. 

Other income (expense), net

Other income (expense), net primarily consists of interest expense on our debt instruments, interest income on our